Andrés F. Vásquez

Dr. Andrés F. Vásquez

Leibniz Institute of Plant Biochemistry (IPB-Halle), Halle, Saxony-Anhalt, Germany
+1
orcid
Computational biochemist exploring natural products, chemodi...

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YHYasser Hayek-Orduz
Yasser Hayek-Orduz
Andrés F. VásquezAndrés F. Vásquez
Andrés F. Vásquez
MVMaría Francisca Villegas-Torres
María Francisca Villegas-Torres
PCPaola A. Caicedo
Paola A. Caicedo
LALuke E. K. Achenie
Luke E. K. Achenie
Andrés Fernando González BarriosAndrés Fernando González Barrios
Andrés Fernando González Barrios
As the world enters its second year of the pandemic caused by SARS-CoV-2, intense efforts have been directed to develop an effective diagnosis, prevention, and treatment strategies. One promising drug target to design COVID-19 treatments is the SARS-CoV-2 Mpro. To date, a comparative understanding of Mprodynamic stereoelectronic interactions with either covalent or non-covalent inhibitors (depending on their interaction with a pocket called S1’ or oxyanion hole) has not been still achieved. In this study, we seek to fill this knowledge gap using a cascade in silico protocol of docking, molecular dynamics simulations, and MM/PBSA in order to elucidate pharmacophore models for both types of inhibitors. After docking and MD analysis, a set of complex-based pharmacophore models was elucidated for covalent and non-covalent categories making use of the residue bonding point feature. The highest ranked models exhibited ROC-AUC values of 0.93 and 0.73, respectively for each category. Interestingly, we observed that the active site region of Mproprotein–ligand complex undergoes large conformational changes, especially within the S2 and S4 subsites. The results reported in this article may be helpful in virtual screening (VS) campaigns to guide the design and discovery of novel small-molecule therapeutic agents against SARS-CoV-2 Mproprotein.

14 January 2026 in Biotechnology Advances
Verified
Journal Article
Open access
QLQiang Liu
Qiang Liu
TWTiantian Wang
Tiantian Wang
BNBinbin Nian
Binbin Nian
FMFeiyang Ma
Feiyang Ma
SZSiqi Zhao
Siqi Zhao
MDMehdi D. Davari
Mehdi D. Davari
Polyphenols and proteins are essential biomolecules that influence food functionality and, by extension, human health. Their interactions-hereafter referred to as PhPIs (Polyphenol-Protein Interactions)- affect key processes such as nutrient bioavailability, antioxidant activity, and therapeutic efficacy. However, these interactions remain challenging due to the structural diversity of polyphenols and the dynamic nature of protein binding. Traditional experimental techniques like nuclear magnetic resonance (NMR) and mass spectrometry (MS), along with computational tools such as molecular docking and molecular dynamics (MD) have offered important insights but face constraints in scalability, throughput, and reproducibility. This review explores how deep learning (DL) is reshaping the study of PhPIs by enabling efficient prediction of binding sites, interaction affinities, and MD using high-dimensional bio- and cheminformatics data. While DL enhances prediction accuracy and reduces experimental redundancy, its effectiveness remains limited by data availability, quality, and representativeness-particularly in the context of natural products. We critically assess current DL frameworks for PhPIs analysis and outline future directions, including multimodal data integration, improved model generalizability, and development of domain-specific benchmark datasets. This synthesis offers guidance for researchers aiming to apply DL in unraveling structure-function relationships of polyphenols, accelerating discovery in nutritional science and therapeutic development.

13 May 2020 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
Andrés F. VásquezAndrés F. Vásquez
Andrés F. Vásquez
AMAlejandro Reyes Muñoz
Alejandro Reyes Muñoz
JDJorge Duitama
Jorge Duitama
Andrés Fernando González BarriosAndrés Fernando González Barrios
Andrés Fernando González Barrios
Cyclin-Dependent Kinase 2 (CDK2) and Vascular Endothelial Growth Factor Receptor (VEGFR2) have largely been considered as attractive targets for developing anticancer agents. However, there is no dual inhibitor commercially available in the market that interacts simultaneously with the allosteric back pocket of these enzymes. We applied a combined computational strategy that started with the generation of two overlapping pharmacophore models of both kinases at ‘inactive’ conformation. Next, several virtual libraries of natural products, including the databases TCM (Traditional Chinese Medicine), UEFS (Universidade Estadual de Feira de Santana), NuBBE (Nuclei of Bioassays, Biosynthesis, and Ecophysiology of Natural Products) and AfroDb (African Medicinal Plants Database) were deconstructed using a non-extensive version of the approach RECAP (retrosynthetic combinatorial analysis procedure). These natural-product-derived fragments (NPDFs) were screened and merged into drug-sized compounds, which were filtered by Lipinski’s Rule-of-five (Ro5) and docking. As a result, two pharmacophore models, namely Hypo1 and Hypo2, were developed with an accuracy of 0.94 and 0.84, respectively. Deconstruction of natural products produced a set of 16655 unique non-extensive NPDFs that were screened against both pharmacophore models. Finally, after merging, Ro5-filtering and docking, we obtained a set of 20 hit compounds predicted to be diverse, developable, synthesizable and potent. The computational strategy proved successful to find virtual candidates of kinase inhibitors and therefore contributes to the identification of innovative multi-target compounds with potential anticancer activity.

16 August 2019 in Frontiers in Chemistry
Verified
Journal Article
Open access
Andrés F. VásquezAndrés F. Vásquez
Andrés F. Vásquez
Andrés Fernando González BarriosAndrés Fernando González Barrios
Andrés Fernando González Barrios
The ligand efficiency (LE) indexes have long been used as decision-making criteria in drug discovery and development. However, in the context of fragment-based drug design (FBDD), these metrics often exhibit a strong emphasis toward the selection of highly efficient “core” fragments for potential optimization, which are not usually considered as parts of a larger molecule with a size typical for a drug. In this study, we present a relative group contribution (RGC) model intended to predict the efficiency of a drug-sized compound in terms of its component fragments. This model could be useful not only in rapidly predicting all the possible combinations of promising fragments from an earlier hit discovery stage, but also in enabling a relatively low-LE fragment to become part of a drug-sized compound as long as it is “rescued” by other high-LE fragments.

Verified
Journal Article
Open access
PDF file
Andrés F. VásquezAndrés F. Vásquez
Andrés F. Vásquez
LGLuis Alberto Gómez
Luis Alberto Gómez
Andrés Fernando González BarriosAndrés Fernando González Barrios
Andrés Fernando González Barrios
Diego Mauricio RIANO PACHONDiego Mauricio RIANO PACHON
Diego Mauricio RIANO PACHON
Antifolates such as methotrexate (MTX) have been largely known as anticancer agents because of their role in blocking nucleic acid synthesis and cell proliferation. Their mechanism of action lies in their ability to inhibit enzymes involved in the folic acid cycle, especially human dihydrofolate reductase (hDHFR). However, most of them have a classical structure that has proven ineffective against melanoma, and, therefore, inhibitors with a non-classical lipophilic structure are increasingly becoming an attractive alternative to circumvent this clinical resistance. In this study, we conducted a protocol combining virtual screening (VS) and cell-based assays to identify new potential non-classical hDHFR inhibitors. Among 173 hit compounds identified (average logP = 3.68; average MW = 378.34 Da), two—herein, called C1 and C2—exhibited activity against melanoma cell lines B16 and A375 by MTT and Trypan-Blue assays. C1 showed cell growth arrest (39% and 56%) and C2 showed potent cytotoxic activity (77% and 51%) in a dose-dependent manner. The effects of C2 on A375 cell viability were greater than MTX (98% vs 60%) at equivalent concentrations and times. Our results indicate that the integrated in silico/in vitro approach provided a benchmark to identify novel promising non-classical DHFR inhibitors showing activity against melanoma cells.

26 September 2024 in Metabolites
Verified
Journal Article
Open access
PDF file
ARAdrián Camilo Rodríguez-Ararat
Adrián Camilo Rodríguez-Ararat
YHYasser Hayek-Orduz
Yasser Hayek-Orduz
Andrés F. VásquezAndrés F. Vásquez
Andrés F. Vásquez
FSFelipe Sierra-Hurtado
Felipe Sierra-Hurtado
MVMaria Francisca Villegas-Torres
Maria Francisca Villegas-Torres
Andrés Fernando González BarriosAndrés Fernando González Barrios
Andrés Fernando González Barrios
Dengue (DENV) and Zika (ZIKV) virus continue to pose significant challenges globally due to their widespread prevalence and severe health implications. Given the absence of effective vaccines and specific therapeutics, targeting the highly conserved NS5 RNA-dependent RNA polymerase (RdRp) domain has emerged as a promising strategy. However, limited efforts have been made to develop inhibitors for this crucial target. In this study, we employed an integrated in silico approach utilizing combinatorial chemistry, docking, molecular dynamics simulations, MM/GBSA, and ADMET studies to target the allosteric N-pocket of DENV3-RdRp and ZIKV-RdRp. Using this methodology, we designed lycorine analogs with natural S-enantiomers (LYCS) and R-enantiomers (LYCR) as potential inhibitors of non-structural protein 5 (NS5) in DENV3 and ZIKV. Notably, 12 lycorine analogs displayed a robust binding free energy (<−9.00 kcal/mol), surpassing that of RdRp-ribavirin (<−7.00 kcal/mol) along with promising ADMET score predictions (<4.00), of which (LYCR728-210, LYCS728-210, LYCR728-212, LYCS505-214) displayed binding properties to both DENV3 and ZIKV targets. Our research highlights the potential of non-nucleoside lycorine-based analogs with different enantiomers that may present different or even completely opposite metabolic, toxicological, and pharmacological profiles as promising candidates for inhibiting NS5-RdRp in ZIKV and DENV3, paving the way for further exploration for the development of effective antiviral agents.